BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

When gene editing company Verve went out seeking new investors for its latest round of funding, existing shareholder GV decided it would rather lead the round itself. GV and existing investors Arch Venture Partners, F-Prime...
BioCentury | Feb 22, 2020
Product Development

Esperion enters crowded LDL-lowering market with FDA approval

FDA’s approval of Nexletol marks Esperion’s transition to a commercial-stage company. Esperion Therapeutics Inc. (NASDAQ:ESPR) plans to launch Nexletol bempedoic acid on March 30. The drug, which is orally administered once-daily, is approved as an...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

Dan Spiegelman stepped down as EVP and CFO at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to pursue other interests. SVP, Finance and Chief Accounting Officer Brian Mueller will serve as acting CFO as the rare diseases company...
BioCentury | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

Amgen will take over full ownership of the 2013 JV it launched with Astellas in Japan but the two will continue to co-promote Amgen’s three drugs in the country. The U.S. biotech has used its...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

Novartis’ $9.7 billion acquisition of The Medicines Co. gives the pharma an RNAi-based cholesterol-lowering therapy that could capture a larger share of the cardiovascular disease market than approved PCSK9 inhibitors have been able to grab....
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...
BioCentury | Oct 26, 2019
Company News

Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

Astellas’ Xospata wins AML approval in Europe The European Commission has approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as a monotherapy for relapsed or refractory acute myelogenous leukemia with an FLT3 Mutation. The oral...
BioCentury | Sep 25, 2019
Clinical News

RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

With readouts now in from three pivotal trials, Medicines Co. could seek a claim of reduced CV risk in its planned regulatory submissions of inclisiran for LDL-C reduction. The announcement of results from the latest...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
Items per page:
1 - 10 of 297